FDA Brief

Warning letters Drugs

FDA warning letter to

Global Pharma Healthcare Private Limited

High riskIssued Oct 20, 2023Posted Nov 14, 2023Center for Drug Evaluation and Research | CDER

FDA warned Global Pharma Healthcare that non-sterile artificial tears and eye ointment from its India plant were tied to a Pseudomonas outbreak with four deaths.

What happened

FDA inspected the company's drug manufacturing facility in Thiruporur, India, from February 20 to March 2, 2023, and reviewed its March 22, 2023 response to the inspection findings. FDA also tested unopened samples of the company's artificial tears and eye ointment and found 18 batches of Artificial Tears and one batch of Artificial Eye Ointment to be non-sterile; two Artificial Tears samples also contained visible foreign particles. Pseudomonas aeruginosa from three batches closely matched more than 85 clinical isolates from an outbreak that affected more than 80 patients and led to 4 deaths and at least 14 cases of vision loss.

What FDA found

  1. The company had no validated aseptic or sterilization process, and its media fills (test runs using growth medium instead of drug) did not properly mimic how the product is actually made.

    21 CFR 211.113(b)
  2. The aseptic filling machine was never properly shown to be suitable, and all batches shipped to the U.S. were made with settings outside the equipment's design specifications.

    21 CFR 211.113(b)
  3. The company did not show its containers and closures keep bacteria out; FDA found that 1 of 20 units of Artificial Eye Ointment batch H29 let microorganisms in.

    21 CFR 211.113(b)
  4. The multi-dose eye products had no preservative to kill microbes and the company never ran antimicrobial effectiveness testing before selling them.

  5. Incoming ingredients and packaging were released on the supplier's certificate of analysis without identity testing or proof the supplier's results were reliable.

    21 CFR 211.84(d)(1) and 211.84(d)(2)
  6. There was no system for monitoring environmental conditions in the aseptic areas and cleaning was inadequate; investigators saw grease-like residue on the filling machine after cleaning.

    21 CFR 211.42(c)(10)(iv) and 211.42(c)(10)(v)

What FDA wants

FDA asks for an independent risk assessment of all contamination hazards, a detailed remediation plan with timelines, corrective action plans for facilities, equipment and staff training, a review of the material and supplier system, and testing of retained high-risk ingredients (such as glycerin and propylene glycol) for diethylene glycol and ethylene glycol, with those test results due within 30 calendar days.

Who should pay attention

  • brands and distributors that put their name on eye drops made by contract manufacturers
  • pharmacies and retailers selling over-the-counter ophthalmic products
  • quality teams that qualify ingredient and packaging suppliers

This is a summary. Read the original letter on fda.gov.

Similar letters to other companies

  1. Shenzhen Benliju Biotech Co., Ltd.

    FDA: Shenzhen Benliju Biotech released OTC drugs labeled sterile without sterility testing or process validation.

    High risk
  2. Northland Nuclear Medicine, LLC

    FDA warned Northland Nuclear Medicine in Bismarck, ND, that its PET drugs are adulterated because it failed to investigate microbial contamination and low yields.

    High risk
  3. Rohto Pharmaceutical Co., Ltd.

    FDA cites Rohto Vietnam eye-drop plant for falsified sterility records, poor aseptic practices, and unapproved Cooling Eye Drops.

    High risk
  4. Jiangmen Shuizirun Sanitary Articles Co., Ltd.

    FDA warns Chinese OTC drug maker Jiangmen Shuizirun for labeling products sterile without sterilizing them or testing for sterility.

    High risk